CD44 and breast carcinoma: The nanoplatform is capable of targeting vascular markers and CD44 overexpressed on the surface of cancer cells through peptides and HA, allowing access to breast cancer cells through multiple barriers and achieving high selectivity for breast cancer cells (Figure 2).